Core Viewpoint - BeiGene's subcutaneous formulation of Tislelizumab has received implied approval from the National Medical Products Administration for clinical trial supplementation, aimed at treating malignant tumors, marking a significant advancement in drug formulation that is expected to enhance patient compliance and market potential [1] Stock Performance - As of February 13, 2026, BeiGene's A-shares (688235) were priced at 279.62 CNY, with a 5-day cumulative increase of 2.61%; Hong Kong shares (06160) were at 208.60 HKD, up 1.66% over the same period; while U.S. shares (ONC.OQ) were at 346.07 USD, down 2.22% [2] - On February 13, 2026, A-share net outflow of main funds was 8.49 million CNY, with a trading volume of 316 million CNY, indicating short-term profit-taking pressure influenced by market sentiment and company events [2] Financial Report Analysis - BeiGene plans to release its financial results for Q4 and the full year of 2025 on February 26, 2026; preliminary data shows a revenue of 27.595 billion CNY for the first nine months of 2025, a year-on-year increase of 44.21%, and a net profit attributable to shareholders of 1.139 billion CNY, up 130.88% year-on-year [3] - The high growth in performance is primarily driven by the sales expansion of core products like Tislelizumab, with investors advised to focus on annual profitability and globalization progress [3] Institutional Perspectives - In the past 90 days, 9 institutions have rated BeiGene, with 8 giving a buy rating and 1 an outperform rating, setting a target average price of 320.0 CNY [4] - Analysts indicate that the company's fundamentals are robust, with strong globalization progress and profitability, although financial risks and market competition should be monitored [4]